NordicRWE is a Norwegian Real-world Evidence (RWE) start-up company that has the ambition to be at the forefront of the data-driven drug development and life cycle process. By tapping into the Nordic health data infrastructure with its long follow-ups, incomparable completeness and extensive linking possibilities, we are uniquely positioned to be a key player in the forthcoming evolution of the RWE supported drug R&D. We provide crucial insight into different steps in the drug development cycle and give evidence that accelerates development, approvals and access as well as benefit/risk surveillance. The Company was established in 2021 and has a strong scientific and commercial team with long-time international experience in epidemiology, advanced analytics, drug R&D and innovation.
Our own R&D project RWE ACCELERATE; NordicRWE was recently awarded a major public research grant from the Research Council of Norway: during the next three years we will turn the unique Nordic health data into new products and services that will accelerate the drug development process. The RWE ACCELERATE project will target two highly relevant and interesting RWE areas:
i. constructing oncology external control arms (ECAs) to emulate and reproduce results from RCT
ii. combining network-based machine learning algorithms and pharmacoepidemiology to identify and validate drug re-purposing candidates and side-effect signals in large registry datasets
Research-focused products and offerings: Our research-based RWE solutions will provide high value evidence for our customers and used to get new and timely insights about the patient journey, to enhance documentation for market access purposes, to support clinical development and to guide decisions for the pipeline. Our goal is to communicate RWE research findings to the wider public community in peer-reviewed journals and at scientific congresses, but also to give our customers added value offerings through our project specific dashboards and utilization of synthetic datasets for feasibility assessments and data exploration.